-
1Academic Journal
Συγγραφείς: S. A. Ivanov, L. O. Petrov, V. V. Kucherov, A. G. Isaeva, A. P. Petrosian, A. A. Izmailov, С. А. Иванов, Л. О. Петров, В. В. Кучеров, А. Г. Исаева, А. П. Петросян, А. А. Измаилов
Πηγή: Research and Practical Medicine Journal; Том 10, № 1 (2023); 134-142 ; Research'n Practical Medicine Journal; Том 10, № 1 (2023); 134-142 ; 2410-1893 ; 10.17709/2410-1893-2023-10-1
Θεματικοί όροι: трансартериальная химиоэмболизация, hepatocellular carcinoma, liver chemoembolization, treatment complications, transarterial chemoembolization, гепатоцеллюлярная карцинома, химиоэмболизация печени, осложнения лечения
Περιγραφή αρχείου: application/pdf
Relation: https://www.rpmj.ru/rpmj/article/view/815/545; Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). Под ред. А. Д. Каприна, В. В. Старинского, А. О. Шахзадовой. М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020, 252 с. Доступно по: https://glavonco.ru/cancer_register/Забол_2019_Электр.pdf, Дата обращения: 29.10.2022.; Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424. https://doi.org/10.3322/caac.21492. Erratum in: CA Cancer J Clin. 2020 Jul;70(4):313; Raoul JL, Gilabert M, Piana G. How to define transarterial chemoembolization failure or refractoriness: a European perspective. Liver Cancer. 2014 May;3(2):119–124. https://doi.org/10.1159/000343867; Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018 Mar 31;391(10127):1301–1314. https://doi.org/10.1016/s0140‑6736(18)30010‑2; Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma.Gastroenterology.2014 Jun;146(7):1691–700.e3.https://doi.org/10.1053/j.gastro.2014.02.032; Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate‑stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014 Sep;11(9):525–535. https://doi.org/10.1038/nrclinonc.2014.122; Yamada R, Nakamura K. [Transcatheter arterial embolization therapy (author’s transl)]. Nihon Rinsho. 1982;40(1):183–190. Japanese.; Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology. 2016 Jul;64(1):106–116. https://doi.org/10.1002/hep.28453; Angle JF, Siddiqi NH, Wallace MJ, Kundu S, Stokes L, Wojak JC, Cardella JF; Society of Interventional Radiology Standards of Practice Committee. Quality improvement guidelines for percutaneous transcatheter embolization: Society of Interventional Radiology Standards of Practice Committee. J Vasc Interv Radiol. 2010 Oct;21(10):1479–1486. https://doi.org/10.1016/j.jvir.2010.06.014; Grover I, Ahmad N, Googe AB. Hepatogastric Fistula following Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma. Case Rep Gastroenterol. 2014 Oct 3;8(3):286–290. https://doi.org/10.1159/000368302; Chen LT, Chen CY, Jan CM, Wang WM, Lan TS, Hsieh MY, Liu GC. Gastrointestinal tract involvement in hepatocellular carcinoma: clinical, radiological and endoscopic studies. Endoscopy. 1990 May;22(3):118–123. https://doi.org/10.1055/s‑2007‑1012815; Hashimoto M, Watanabe G, Matsuda M, Yamamoto T, Tsutsumi K, Tsurumaru M: Case report: gastrointestinal bleeding from a hepatocellular carcinoma invading the transverse colon. J Gastroenterol Hepatol. 1996;11(8):765–767. https://doi.org/10.1111/j.1440‑1746.1996.tb00328.x; Park MS, Kim KW, Yu JS, Kim MJ, Yoon SW, Chung KW, et al. Radiologic findings of gastrointestinal tract involvement in hepatocellular carcinoma. J Comput Assist Tomogr. 2002 Jan‑Feb;26(1):95–101. https://doi.org/10.1097/00004728‑200201000‑00014; Sayana H, Yousef O, Clarkston WK. Massive upper gastrointestinal hemorrhage due to invasive hepatocellular carcinoma and hepato‑gastric fistula. World J Gastroenterol. 2013 Nov 14;19(42):7472–7475. https://doi.org/10.3748/wjg.v19.i42.7472; https://www.rpmj.ru/rpmj/article/view/815
-
2Academic Journal
Συγγραφείς: A. V. Gorbatykh, O. E. Latkin, A. A. Prokhorikhin, D. D. Zubarev, M. A. Chernyavsky, А. В. Горбатых, О. Е. Латкин, А. А. Прохорихин, Д. Д. Зубарев, М. А. Чернявский
Πηγή: Translational Medicine; Том 9, № 4 (2022); 33-40 ; Трансляционная медицина; Том 9, № 4 (2022); 33-40 ; 2410-5155 ; 2311-4495
Θεματικοί όροι: трансартериальная химиоэмболизация с применением насыщенных сфер, intra-arterial delivery of nanoparticles, selective internal radiation therapy, transarterial chemoembolization, transarterial chemoembolization with drug-eluting microspheres, transarterial oily chemoembolization, интервенционная онкология, масляная трансартериальная химиоэмболизация, селективная лучевая терапия, трансартериальная химиоэмболизация
Περιγραφή αρχείου: application/pdf
Relation: https://transmed.almazovcentre.ru/jour/article/view/734/478; Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646–674. DOI:10.1016/j.cell.2011.02.013.; Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018; 15(2):81–94. DOI:10.1038/nrclinonc.2017.166.; Easwaran H, Tsai HC, Baylin SB. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell. 2014; 54(5):716–727. DOI:10.1016/j.molcel.2014.05.015.; Sawyers C. Targeted cancer therapy. Nature. 2004;432(7015):294–297. DOI:10.1038/nature03095.; Adam A, Kenny LM. Interventional oncology in multidisciplinary cancer treatment in the 21(st) century. Nat Rev Clin Oncol. 2015; 12(2):105–113. DOI:10.1038/nrclinonc.2014.211.; European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018; 69(1):182–236. DOI:10.1016/j.jhep.2018.03.019.; Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018; 68(2):723– 750. DOI:10.1002/hep.29913.; Mahnken AH, Pereira PL, de Baère T. Interventional oncologic approaches to liver metastases. Radiology. 2013; 266(2):407–430. DOI:10.1148/radiol.12112544.; Duran R, Chapiro J, Schernthaner RE, et al. Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions. Br J Radiol. 2015; 88(1052):20140564. DOI:10.1259/bjr.20140564.; Lencioni R, de Baere T, Soulen MC, et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology. 2016; 64(1):106–116. DOI:10.1002/hep.28453.; Trédan O, Galmarini CM, Patel K, et al. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 2007; 99(19):1441–1454. DOI:10.1093/jnci/djm135.; Idée JM, Guiu B. Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review. Crit Rev Oncol Hematol. 2013; 88(3):530–549. DOI:10.1016/j.critrevonc.2013.07.003.; Deschamps F, Farouil G, Gonzalez W, et al. Stabilization Improves Theranostic Properties of Lipiodol®-Based Emulsion During Liver Trans-arterial Chemo-embolization in a VX2 Rabbit Model. Cardiovasc Intervent Radiol. 2017; 40(6):907–913. DOI:10.1007/s00270-017-1616-2.; Deschamps F, Harris KR, Moine L, et al. PickeringEmulsion for Liver Trans-Arterial Chemo-Embolization with Oxaliplatin. Cardiovasc Intervent Radiol. 2018; 41(5):781–788. DOI:10.1007/s00270-018-1899-y.; Fuchs K, Duran R, Denys A, et al. Drug-eluting embolic microspheres for local drug delivery — State of the art. J Control Release. 2017; 262:127–138. DOI:10.1016/j.jconrel.2017.07.016.; Brown KT, Do RK, Gonen M, et al. Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone. J Clin Oncol. 2016; 34(17):2046–2053. DOI:10.1200/JCO.2015.64.0821.; Caine M, Zhang X, Hill M, et al. Comparison of microsphere penetration with LC Bead LUMI™ versus other commercial microspheres. J Mech Behav Biomed Mater. 2018; 78:46–55. DOI:10.1016/j.jmbbm.2017.10.034.; Tian M, Lu W, Zhang R, et al. Tumor uptake of hollow gold nanospheres after intravenous and intra-arterial injection: PET/CT study in a rabbit VX2 liver cancer model. Mol Imaging Biol. 2013; 15(5):614–624. DOI:10.1007/s11307-013-0635-x.; Lee IJ, Ahn CH, Cha EJ, et al. Improved drug targeting to liver tumors after intra-arterial delivery using superparamagnetic iron oxide and iodized oil: preclinical study in a rabbit model. Invest Radiol. 2013; 48(12):826– 833. DOI:10.1097/RLI.0b013e31829c13ef.; Mouli SK, Tyler P, McDevitt JL, et al. Imageguided local delivery strategies enhance therapeutic nanoparticle uptake in solid tumors. ACS Nano. 2013; 7(9):7724–7733. DOI:10.1021/nn4023119.; Jeon MJ, Gordon AC, Larson AC, et al. Transcatheter intra-arterial infusion of doxorubicin loaded porous magnetic nano-clusters with iodinated oil for the treatment of liver cancer. Biomaterials. 2016; 88:25–33. DOI:10.1016/j.biomaterials.2016.02.021.; Liang Q, Wang YX, Ding JS, et al. Intra-arterial delivery of superparamagnetic iron-oxide nanoshell and polyvinyl alcohol based chemoembolization system for the treatment of liver tumor. Discov Med. 2017; 23(124):27–39.; Duran R, Mirpour S, Pekurovsky V, et al. Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer. Clin Cancer Res. 2017; 23(2):536–548. DOI:10.1158/1078-0432.CCR-16-0725.; Salem R, Gordon AC, Mouli S, et al. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. Gastroenterology. 2016; 151(6):1155–1163.e2. DOI:10.1053/j.gastro.2016.08.029.; Theysohn JM, Ertle J, Müller S, et al. Hepatic volume changes after lobar selective internal radiation therapy (SIRT) of hepatocellular carcinoma. Clin Radiol. 2014; 69(2):172–178. DOI:10.1016/j.crad.2013.09.009.; Pavel M, O’Toole D, Costa F, et al. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology. 2016; 103(2):172–85. DOI:10.1159/000443167.; Sangro B, Iñarrairaegui M, Bilbao JI. Radioembolization for hepatocellular carcinoma. J Hepatol. 2012; 56(2):464–73. DOI:10.1016/j.jhep.2011.07.012.; Van Der Gucht A, Jreige M, Denys A, et al. Resin Versus Glass Microspheres for 90Y Transarterial Radioembolization: Comparing Survival in Unresectable Hepatocellular Carcinoma Using Pretreatment Partition Model Dosimetry. J Nucl Med. 2017; 58(8):1334–1340. DOI:10.2967/jnumed.116.184713.; Wagstaff PG, Buijs M, van den Bos W, et al. Irreversible electroporation: state of the art. Onco Targets Ther. 2016; 9:2437–2446. DOI:10.2147/OTT.S88086.; Bhutiani N, Agle S, Li Y, et al. Irreversible electroporation enhances delivery of gemcitabine to pancreatic adenocarcinoma. J Surg Oncol. 2016;114(2):181– 186. DOI:10.1002/jso.24288.; Srimathveeravalli G, Abdel-Atti D, Pérez-Medina C, et al. Reversible Electroporation-Mediated Liposomal Doxorubicin Delivery to Tumors Can Be Monitored With 89Zr-Labeled Reporter Nanoparticles. Mol Imaging. 2018; 17:1536012117749726. DOI:10.1177/1536012117749726.; Tempany CM, McDannold NJ, Hynynen K, et al. Focused ultrasound surgery in oncology: overview and principles. Radiology. 2011; 259(1):39–56. DOI:10.1148/radiol.11100155.; Cheung TT, Fan ST, Chan SC, et al. Highintensity focused ultrasound ablation: an effective bridging therapy for hepatocellular carcinoma patients. World J Gastroenterol. 2013; 19(20):3083–3089. DOI:10.3748/wjg. v19.i20.3083.; de Smet M, Heijman E, Langereis S, et al. Magnetic resonance imaging of high intensity focused ultrasound mediated drug delivery from temperaturesensitive liposomes: an in vivo proof-of-concept study. J Control Release. 2011; 150(1):102–110. DOI:10.1016/j.jconrel.2010.10.036.; Parchur AK, Sharma G, Jagtap JM, et al. Vascular Interventional Radiology-Guided Photothermal Therapy of Colorectal Cancer Liver Metastasis with Theranostic Gold Nanorods. ACS Nano. 2018; 12(7):6597–6611. DOI:10.1021/acsnano.8b01424.; Li J, Zhou M, Liu F, et al. Hepatocellular Carcinoma: Intra-arterial Delivery of Doxorubicin-loaded Hollow Gold Nanospheres for Photothermal AblationChemoembolization Therapy in Rats. Radiology. 2016; 281(2):427–435. DOI:10.1148/radiol.2016152510.; Duran R, Namur J, Pascale F, et al. Vandetanibeluting Radiopaque Beads: Pharmacokinetics, Safety, and Efficacy in a Rabbit Model of Liver Cancer. Radiology. 2019; 293(3):695–703. DOI:10.1148/radiol.2019190305.; Bize P, Duran R, Fuchs K, et al. Antitumoral Effect of Sunitinib-eluting Beads in the Rabbit VX2 Tumor Model. Radiology. 2016; 280(2):425–435. DOI:10.1148/radiol.2016150361.; Ahmed N, Fessi H, Elaissari A. Theranostic applications of nanoparticles in cancer. Drug Discov Today. 2012; 17(17-18):928–934. DOI:10.1016/j.drudis.2012.03.010.; https://transmed.almazovcentre.ru/jour/article/view/734
-
3Academic Journal
Συγγραφείς: V.S. Trifanov, E.N. Kolesnikov, M.Yu. Meshcheryakova, A.V. Snezhko, A.L. Bazaev, M.N. Chernyak
Πηγή: Yakut Medical Journal. :109-111
Θεματικοί όροι: 2. Zero hunger, нейроэндокринноклеточная опухоль, критерии RECIST 1.1, RECIST 1.1 criteria, transarterial chemoembolism, metastasis, трансартериальная химиоэмболизация, метастаз, neuroendocrine cell tumor, 3. Good health
-
4Academic Journal
Συγγραφείς: Petkau, V. V., Breder, V. V., Bessonova, E. N., Laktionov, K. K., Stilidi, I. S., Петкау, В. В., Бредер, В. В., Бессонова, Е. Н., Лактионов, К. К., Стилиди, И. С.
Θεματικοί όροι: HEPATOCELLULAR CARCINOMA (HCC), LIVER CANCER, COVID-19, CORONAVIRUS, TARGETED THERAPY, TRANSARTERIAL CHEMOEMBOLIZATION (TACE), ГЕПАТОЦЕЛЛЮЛЯРНЫЙ РАК (ГЦР), РАК ПЕЧЕНИ, КОРОНАВИРУС, ТАРГЕТНАЯ ТЕРАПИЯ, ТРАНСАРТЕРИАЛЬНАЯ ХИМИОЭМБОЛИЗАЦИЯ (ТАХЭ)
Περιγραφή αρχείου: application/pdf
Relation: Scopus; http://elib.usma.ru/handle/usma/7166
Διαθεσιμότητα: http://elib.usma.ru/handle/usma/7166
-
5Academic Journal
Συγγραφείς: V. V. Breder, M. U. Pitkevich, E. R. Virshke, L. A. Kostyakova, I. A. Dzhanyan, K. K. Laktionov, В. В. Бредер, М. Ю. Питкевич, Э. Р. Виршке, Л. А. Костякова, И. А. Джанян, К. К. Лактионов
Πηγή: Meditsinskiy sovet = Medical Council; № 10 (2018); 27-32 ; Медицинский Совет; № 10 (2018); 27-32 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2018-10
Θεματικοί όροι: BCLC, HCC, transarterial chemoembolization (TACE), sorafenib, regorafenib, ГЦР, трансартериальная химиоэмболизация (ТАХЭ), сорафениб, регорафениб
Περιγραφή αρχείου: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/2529/2497; Siegel R et al. Cancer statistics, 2014. CA. Cancer J Clin, 2014. 64(1): 9–29.; Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2012 году. Известия Тинро, 2014. 226: 1-226.; Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2013 году. ФГБУ «МНИОИ им. П.А. Герцена» Минздрава России, 2014. 235 с.; Bruix J et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol, 2001, 35(3): 421–430.; Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg, 1964, 1: 1–85.; Uehara T et al. Molecular mechanisms of fibrosis-associated promotion of liver carcinogenesis. Toxicological sciences, 2013, 132(1): 53–63.; Бредер В.В. Стратегия и тактика консервативного лечения гепатоцеллюлярного рака, 2017.; Di Costanzo GG, Tortora R, Intermediate hepatocellular carcinoma: How to choose the best treatment modality? World J Hepatol, 2015 May 28, 7(9): 1184-1191.; EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma J Hepatol, 2018. Doi:10.1016/j.jhep.2018.03.019.; Виршке Э.Р., Косырев В.Ю., Долгушин Б.И. Гепатоцеллюлярный рак, BCLC-B: в поисках оптимального лечения. Интервенционные радиологические технологии в лечении больных ГЦР. Злокачественные опухоли, 2016, 4(спецвып. 1): 26–28.; Huppert P. Current concepts in transarterial chemoembolization of hepatocellular carcinoma. Abdom Imaging, 2011, 36(6): 677-683.; Aerts M et al. Current status and perspectives of immune-based therapies forhepatocellular carcinoma. World J Gastroenterol, 2016, 22(1): 253–261.; Ali MY et al. Activation of dendritic cells by local ablation of hepatocellular carcinoma. J Hepatol Elsevier, 2005, 43(5): 817–822.; Zerbini A et al. Radiofrequency Thermal Ablation of Hepatocellular Carcinoma Liver Nodules Can Activate and Enhance TumorSpecific T-Cell Responses. Cancer Res, 2006, 66(2).; Bolondi L et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: Proposal for a subclassification to facilitate treatment decisions Semin Liver Dis, 2012, 32(4): 348–359.; Llovet JM et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet, 2002, 359(9319): 1734-9.; Terzi E et al. Response rate and clinical outcome of HCC after first and repeated cTACE performed on demand. J Hepatol, 2012, 57(6): 1258-67.; Sieghart W et al. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology, 2013, 57: 2261–2273.; Kadalayil L et al. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol, 2013, 24(10): 2565–2570.; Hucke F et al. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. J Hepatol, 2014, 61(6): 1287-1296.; Arizumi T et al. Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma. Liver Cancer, 2015 Dec, 4(4): 253–262.; Kudo M et al. JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 Update by the liver cancer study group of Japan. Liver Cancer, 2014, 3(3–4): 458–468.; Raoul JL et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treatment Reviews, 2011: 212-220.; Colombo M et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med, 1991, 325: 675-680.; Ioannou GN et al. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol Elsevier, 2007, 5(8): 938–945, 945-4.; Cabibbo G et al. Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study. World J Hepatol, 2012, 4(9): 256– 261.; Leung TWT et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res, 1999, 5(7): 1676– 1681.; Llovet JM et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008, 359(4): 378-390.; Cheng A-L et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebocontrolled trial. Lancet Oncol Elsevier, 2009, 10(1): 25–3.; Iavarone M et al. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology, 2011, 54(6): 2055-63.; Ganten TM et al. Sorafenib in patients with hepatocellular carcinoma – results of the observational INSIGHT study. Clin Cancer Res, 2017, 23(19): 5720–5728.; Strumberg D, Schultheis B. Regorafenib for cancer. Expert Opin Investig Drugs, 2012, 21(6): 879–889.; Bruix J et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 2016, 0(0): 1020–1022.; Finn RS et al. Proc ASCO GI. San Francisco, USA, 19–21 Jan 2017, abstract 344.; Lencioni R. Chemoembolization in Patients with Hepatocellular Carcinoma. Liver Cancer, 2012, 1(1): 41–50.; Meyer T et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol, 2017, 2: 565–75.; Kudo M et al. Randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. J Clin Oncol, 2018, 36(suppl, abstr 4017).
-
6Academic Journal
Συγγραφείς: E. R. Virshke, V. Ju. Kosyrev, B. I. Dolgushin, Э. Р. Виршке, В. Ю. Косырев, Б. И. Долгушин
Πηγή: Malignant tumours; № 4s1 (2016); 26-28 ; Злокачественные опухоли; № 4s1 (2016); 26-28 ; 2587-6813 ; 2224-5057
Θεματικοί όροι: трансартериальная химиоэмболизация, интервенционные радиологические технологии, локорегионарное лечение
Περιγραφή αρχείου: application/pdf
Relation: https://www.malignanttumors.org/jour/article/view/281/251; Cormier J. N., Thomas K. T., Chari R. S. et al. Management of hepatocellular carcinoma // J. of Gastrointestinal Surgery.– 2006.– Vol. 10.– № 5.– P. 761–780.; Llovet J. M., Fuster J., Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. // Liver transplantation.– 2004.– Vol. 10 (2 suppl.1).– P. 115–120.; Zhou Y, Zhao Y, Li B, Xu D, Yin Z, Xie F, Yang J., Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. BMC Gastroenterology 2010, 10:78.; Jia-Yan Ni. Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2013 June 28; 19(24): 3872–388.; Peng ZW, Zhang YJ, Chen MS, Xu L, Liang HH, Lin XJ, Guo RP, Zhang YQ, Lau WY. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol. 2013 Feb 1;31(4):426–32.; M. Ginsburg, Sean P Zivin, K. Wroblewski et al. Comparison of Combination Therapies in the Management of Hepatocellular Carcinoma: Transarterial Chemoembolization with Radiofrequency Ablation versus Microwave Ablation // Radiology Journal of Vascular and Interventional. Volume 26, Issue 3r March 2015, Pages 330–341.; Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Tibballs J, Meyer T, Patch DW, Burroughs AK. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30: 625.; Bargellini I, Florio F, Golfieri R, Grosso M, Lauretti DL, Cioni R. Trends in utilization of transarterial treatments for hepatocellular carcinoma: results of a survey by the Italian Society of Interventional Radiology. Cardiovasc Intervent Radiol 2014; 37: 438444.; Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 5260.; European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASLEORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908943.; Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 11641171.; Llovet JM, Real MI, Monta a X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sol R, Rod s J, Bruix J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 17341739.; Terzi E, Golfieri R, Piscaglia F, Galassi M, Dazzi A, Leoni S, Giampalma E, Renzulli M, Bolondi L. Response rate and clinical outcome of HCC after first and repeated cTACE performed «on demand». J Hepatol 2012; 57: 12581267.; Bolondi L, Burroughs A, Dufour JF, Galle PR, Mazzaferro V, Piscaglia F, Raoul JL, Sangro B. Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis 2012; 32: 348359.; Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M, Sergent G, Pfammatter T, Terraz S, Benhamou Y, Avajon Y, Gruenberger T, Pomoni M, Langenberger H, Schuchmann M, Dumortier J, Mueller C, Chevallier P, Lencioni R. Prospective randomized study of doxorubicinelutingbead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33: 4152.; Xie F, Zang J, Guo X, Xu F, Shen R, Yan L, Yang J, He J. Comparison of transcatheter arterial chemoembolization and microsphere embolization for treatment of unresectable hepatocellular carcinoma: a metaanalysis. J Cancer Res Clin Oncol 2012; 138: 455462.; Golfieri R, Giampalma E, Renzulli M, Cioni R, Bargellini I, Bartolozzi C, Breatta AD, Gandini G, Nani R, Gasparini D, Cucchetti A, Bolondi L, Trevisani F. Randomised controlled trial of doxorubicineluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 2014; 111: 255264.; Chok KS, Cheung TT, Lo RC, Chu FS, Tsang SH, Chan AC, Sharr WW, Fung JY, Dai WC, Chan SC, Fan ST, Lo CM. Pilot study of high-intensity focused ultrasound ablation as a bridging therapy for hepatocellular carcinoma patients wait-listed for liver transplantation. Liver Transpl 2014; 20: 912–921; 19. Cescon M, Cucchetti A, Ravaioli M, Pinna AD. Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate. J Hepatol 2013; 58: 609–618.; https://www.malignanttumors.org/jour/article/view/281; undefined
Διαθεσιμότητα: https://www.malignanttumors.org/jour/article/view/281
-
7Academic Journal
Συγγραφείς: ВИРШКЕ Э. Р., КОСЫРЕВ В. Ю., ДОЛГУШИН Б. И.
Θεματικοί όροι: гепатоцеллюлярный рак, интервенционные радиологические технологии, локорегионарное лечение, трансартериальная химиоэмболизация
Περιγραφή αρχείου: text/html
-
8Academic Journal
Πηγή: Злокачественные опухоли.
Θεματικοί όροι: 03 medical and health sciences, гепатоцеллюлярный рак, интервенционные радиологические технологии, локорегионарное лечение, трансартериальная химиоэмболизация, 0302 clinical medicine
Περιγραφή αρχείου: text/html
-
9Academic Journal
-
10Academic Journal
Συγγραφείς: Загорулько А.И., Черняев М.В., Козлов Д.В., Голубцов А.К.
Πηγή: Лабораторная и клиническая медицина. Фармация
Θεματικοί όροι: head and neck squamous cell carcinoma, transarterial chemoembolization, intraarterial chemoinfusion, плоскоклеточный рака головы и шеи, трансартериальная химиоэмболизация, внутриартериальная химиоинфузия
Διαθεσιμότητα: https://repository.rudn.ru/records/article/record/110896/
